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chemosensitivity of tumours. The concept was realized in the MUNICON-1
and -2 trials [Lordick F et al. Lancet Oncol 2007; Lordick et al. ASCO-GI
2011]. These trials prospectively conﬁrmed that responders to induction
chemotherapy can be identiﬁed by early metabolic imaging using FDG-
PET. Continued neoadjuvant chemotherapy in the responding population
resulted in a favourable outcome: The median overall survival was not
reached in metabolic responders as compared to 26 months and 18
months in metabolical non-responders in MUNICON-1 and -2, respectively.
MUNICON-1 showed that chemotherapy can be discontinued at an early
stage in metabolic non-responders, thereby saving time and reducing side-
effects and costs. Compared to previous studies one could delineate that
the outcome of metabolic non-responders was at least not compromised
by the early discontinuation of chemotherapy. MUNICON-2 showed that the
addition of neoadjuvant radiation therapy in metabolic non-responders does
not lead to an evident improvement of the poor prognosis, thus showing
that early metabolic non-response indicates a dismal tumour biology.
Based on these results, the integration of FDG-PET can be recommended
for further clinical studies. Important questions need to be addressed:
Does metabolic non-response to induction chemotherapy stand for a
deﬁnite unfavourable outcome or can further treatment modiﬁcations lead
to improved response rates and outcome? Do patients with early metabolic
non-response beneﬁt from surgery? At this stage we feel that surgery
offers a considerable amount of local control, at least, and is therefore
indicated as the treatment of choice in metabolic non-responders. However,
non-surgical local treatment, like chemoradiation, might offer the same
magnitude of local control and clinical beneﬁt in metabolic non-responders.
These questions should be addressed in future randomized trials.
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Molecular Imaging for Personalised Treatment of Malignant
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Malignant lymphomas comprise a heterogeneous group of malignancies,
including both indolent and highly aggressive diseases, and localised and
disseminated disease presentations. Lymphomas are generally sensitive to
therapy, and the goal of therapy is cure or very long-term disease control.
High cure rates and long-term survival mean that patients, frequently young
at diagnosis, are subject to the serious long-term of chemotherapy and
radiotherapy, and the resulting excess morbidity and mortality is substantial.
Management of malignant lymphoma is thus a balance between cure and
toxicity, between over-treatment and under-treatment. The right treatment
for the individual patient is an individualised treatment. With no access
to highly accurate pre-treatment predictive markers, an individualised
treatment should be tailored to the individual patient’s risk and treatment
response.
Molecular imaging, and in particular FDG-PET/CT, has become a
cornerstone imaging procedure in most malignant lymphomas. The
very high diagnostic accuracy at staging provides better pre-treatment
assessment of disease extent and a better basis for accurate deﬁnition of
highly conformal radiation therapy volumes. FDG-PET is the most powerful
predictor of treatment response and prognosis in aggressive lymphomas,
and the metabolic response assessment is possible very early during
therapy, as opposed to response assessment by conventional imaging
procedures. An early in-vivo treatment sensitivity test, rather than a late
structural response assessment, makes it possible to adjust the individual
patient’s therapy according to the early treatment response. FDG-PET/CT
is a key determinant of treatment response according to the revised
international response criteria for aggressive lymphoma, due to a very high
negative predictive value of post-therapy FDG-PET.
Other PET tracers than FDG have a potential role in the management of
lymphoma, and they will be discussed brieﬂy in this presentation, as well as
the role of FDG-PET/CT in other clinical settings, such as follow-up/routine
surveillance and the management of relapsed lymphoma. The presentation
will also provide an overview of ongoing clinical trials investigating the role
of PET-response adapted lymphoma therapy.
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Surgical removal of intrisinc cerebral neoplasms requires the combined
efforts of a multidisclipinary team of neurosurgeon, neuroradiologist, neu-
ropsychologist, neurophysiologist, and neurooncologists that all together
contribute in the deﬁnition of the location, extension, and extent of functional
involvement that a speciﬁc lesion has induced in a particular patient.
Each tumour has induced particular and speciﬁc changes of the functional
network, that varies among patients. This requires that each treatment plan
should be tailored to the tumour and to the patient. When this is reached,
surgery should be accomplished according to functional and anatomical
boundaries, and has to aim to the maximal resection with the maximal
patient functional preservation. This can be reached at the time of the
initial surgery, depending on the functional organization of the brain, or
may require additional surgeries, eventually intermingled with adjuvant
treatments. The use of so called brain mapping techniques extend surgical
indications, improve extent of resection with greater oncological impact,
minimization of morbidity and increase in quality of life. To achieve the goal
of a satisfactory tumour resection associated with the full preservation of
the patients abilities, a series of neuropsychological, neurophysiological,
neuroradiological and intraoperative investigations have to be performed.
In this talk, we will describe the rationale, the indications and the modality
for performing a safe and rewarding surgical removal of low grade gliomas
by using these techniques, as well as the functional and oncological results.
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Stem Cells in Brain Tumours − Where Are We Going?
R. De Maria1. 1Istituto Superiore di Sanita`, Hematology Oncology and
Molecular Medicine, Roma, Italy
Cancer stem cells (CSCs) are the rare population of undifferentiated
tumorigenic cells that are responsible for tumour initiation, mainteinance
and spreading. The existence of CSCs might explain why tumours are
resistant to conventional therapies, which typically target the rapidly
proliferating tumour cells but spare the slow dividing tumour stem cell
population. Moreover, these cells seem to be intrinsically more resistant to
apoptosis inducing stimuli. Indeed, resistance of brain tumours to current
therapies may be related to the presence of CSCs, as shown by several
studies that examined their role in the development of resistance to
radiation and chemotherapy.
Hence, the discovery of CSCs has profound implications for the
development of more effective treatments, since the selective targeting of
these cells might lead to the eradication of the tumour. Different strategies
towards CSC targeting are being investigated. One of such approach is
forcing these cells to differentiate, rendering them vulnerable to therapy.
Likewise, targeted therapies able to hinder the CSC survival machinery
might prove to be higly effective. The main challenge towards this direction,
however, remains the need for a full molecular characterization of CSCs.
We are currently characterizing at different levels, including genome-
wide expression of mRNA, microRNA and proteome proﬁling, CSCs from
glioblastoma. Such extensive characterization may provide key information
on the relavant pathways to be targeted for successfull therapies.
Novel CSC targeted therapy strategies in brain tumours might also
arise from the recent demonstration that a signiﬁcant portion of the
vascular endothelium in glioblastoma derives from CSCs. Most importantly,
the functional relavance of the CSC-derived endothelial vessels was
established by the selective targeting of endothelial cells generated by
CSCs in mouse xenografts, which resulted in tumour reduction and
degeneration.
In conclusion, although the identiﬁcation of CSCs is relatively recenbt,
this research area appears extremely promising as it may signiﬁcantly
contribute to the rational design of new therapeutic approaches for brain
cancer.
